ENTITY
CARSgen Therapeutics

CARSgen Therapeutics (2171 HK)

23
Analysis
Health CareChina
CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has relationships with Shanghai Cancer Institute and Shanghai Renji Hospital, plans to initiate clinical trials for KJgpc3-001, a glypican-3 (GPC3)-directed CAR-T cell therapy.
more
Publication Icon
No publications yet
There aren’t any sponsored reports right now
Back to "All"
x